These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
elect the two nominees for Class I director named in the proxy statement, each to hold office until our 2022 annual meeting of stockholders and until their respective successors are duly elected and qualified;
|
|
•
|
approve, on an advisory basis, the compensation of our named executive officers for the year ended
December 31, 2018
, as set forth in the proxy statement; and
|
|
•
|
ratify the appointment by the audit committee of our board of directors of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending
December 31, 2019
.
|
|
Time and Date
|
8:30 a.m., Pacific time, on Thursday, May 9, 2019
|
|
|
Place
|
MaxLinear’s office, 50 Parker, Irvine, California 92618
|
|
|
Items of Business
|
•
|
To elect the two nominees for Class I director named in the proxy statement, each to hold office until our 2022 annual meeting of stockholders and until their respective successors are duly elected and qualified.
|
|
|
•
|
To approve, on an advisory basis, the compensation of our named executive officers for the year ended December 31, 2018, as set forth in the proxy statement.
|
|
|
•
|
To ratify the appointment by the audit committee of our board of directors of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
|
|
•
|
To transact any other business that may properly come before the 2019 annual meeting or any postponement or adjournment thereof.
|
|
Adjournments and Postponements
|
Any action on the items of business described above may be considered at the annual meeting at the time and on the date specified above or at any time and date to which the annual meeting may be properly adjourned or postponed.
|
|
|
Record Date
|
You are entitled to vote only if you were a MaxLinear stockholder of record as of the close of business on the record date of March 25, 2019.
|
|
|
Meeting Admission
|
You are entitled to attend the annual meeting only if you were a MaxLinear stockholder as of the close of business on the record date or otherwise hold a valid proxy for the annual meeting.
If you are not a stockholder of record but hold shares through a broker, bank, trustee, or nominee (i.e., in street name), you should provide proof of beneficial ownership as of the record date, a copy of the voting instruction card provided by your broker, bank, trustee, or nominee, or similar evidence of ownership.
|
|
|
|
Please let us know if you plan to attend the meeting by marking the appropriate box on the enclosed proxy card or, if you vote by telephone or over the Internet, by indicating your plans when prompted.
|
|
|
Annual Report
|
Our 2018 annual report is enclosed with these materials as a separate booklet. You may also access our 2018 annual report by visiting www.edocumentview.com/MXL. Our 2018 annual report is not a part of the proxy solicitation materials.
|
|
|
Voting
|
Your vote is very important. Whether or not you plan to attend the annual meeting, we encourage you to read the proxy statement and submit your proxy or voting instructions as soon as possible. For specific instructions on how to vote your shares, please refer to the instructions in the section entitled Questions and Answers About the Proxy Materials and Annual Meeting beginning on page 1 of this proxy statement, or your enclosed proxy card.
|
|
|
Page
|
|
|
•
|
To elect two nominees for Class I director named in this proxy statement, each to hold office until our 2022 annual meeting of stockholders and until their respective successors are duly elected and qualified.
|
|
•
|
To approve, on an advisory basis, the compensation of our named executive officers for the year ended
December 31, 2018
, as set forth in this proxy statement.
|
|
•
|
To ratify the appointment by the audit committee of our board of directors of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending
December 31, 2019
.
|
|
•
|
To transact any other business that properly comes before the annual meeting or any postponement or adjournment thereof.
|
|
•
|
“FOR” the two nominees for Class I director named in this proxy statement, each to hold office until our 2022 annual meeting of stockholders and until their respective successors are duly elected and qualified.
|
|
•
|
“FOR” the approval, on an advisory basis, of the compensation of our named executive officers for the year ended
December 31, 2018
, as set forth in this proxy statement.
|
|
•
|
“FOR” the ratification of the appointment by the audit committee of our board of directors of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending
December 31, 2019
.
|
|
Proposal
|
|
Vote Required
|
|
Discretionary Voting Allowed?
|
|
Election of two nominees for Class I director named in this proxy statement, each to hold office until 2022 annual meeting of stockholders and until their respective successors are duly elected and qualified.
|
|
Votes cast for such nominee’s election exceed the votes cast against such nominee’s election
|
|
No
|
|
To approve, on an advisory basis, the compensation of our named executive officers for the year ended December 31, 2018.
|
|
Majority of the votes cast
|
|
No
|
|
Ratification of the appointment by the audit committee of our board of directors of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
|
|
Majority of the votes cast
|
|
Yes
|
|
•
|
not earlier than
January 25, 2020
; and
|
|
•
|
not later than the close of business on
February 24, 2020
.
|
|
•
|
the 90th day before such annual meeting; or
|
|
•
|
the 10th day following the day on which public announcement of the date of such meeting is first made.
|
|
•
|
coordinating and moderating executive sessions of our independent directors;
|
|
•
|
advising Dr. Seendripu as to the quality, quantity, and timeliness of the flow of information from management that is necessary for the independent directors to effectively and responsibly perform their duties;
|
|
•
|
confirming the agenda with Dr. Seendripu for meetings of our board of directors;
|
|
•
|
holding regular update sessions with Dr. Seendripu;
|
|
•
|
acting as the principal liaison between the independent directors and Dr. Seendripu on sensitive issues; and
|
|
•
|
performing such other duties as our board of directors may from time to time delegate to the Lead Director to assist our board of directors in the fulfillment of its responsibilities.
|
|
•
|
oversees the work of our independent registered public accounting firm;
|
|
•
|
approves the hiring, discharge, and compensation of our independent registered public accounting firm;
|
|
•
|
approves engagements of the independent registered public accounting firm to render any audit or permissible non-audit services;
|
|
•
|
reviews the qualifications, independence, and performance of the independent registered public accounting firm;
|
|
•
|
reviews our financial statements and our critical accounting policies and estimates;
|
|
•
|
reviews management’s assessment of our internal controls; and
|
|
•
|
reviews and discusses with management and the independent auditors the results of our annual audit, our quarterly financial statements, and our publicly filed reports.
|
|
•
|
reviews and recommends policies relating to compensation and benefits of our executive officers and employees;
|
|
•
|
reviews and approves corporate goals and objectives relevant to compensation of our chief executive officer and other executive officers;
|
|
•
|
evaluates the performance of our executive officers in light of established goals and objectives;
|
|
•
|
recommends compensation of our executive officers based on its evaluations; and
|
|
•
|
administers the issuance of stock options, restricted stock units, and other awards under our equity incentive plans.
|
|
•
|
evaluates and makes recommendations regarding the organization and governance of the board of directors and its committees;
|
|
•
|
assesses the performance of members of the board of directors and makes recommendations regarding committee and chair assignments;
|
|
•
|
recommends desired qualifications for board of directors membership and conducts searches for potential members of the board of directors; and
|
|
•
|
reviews and makes recommendations with regard to our corporate governance guidelines.
|
|
•
|
the current size and composition of our board of directors and the needs of the board and its respective committees;
|
|
•
|
factors such as character, integrity, judgment, diversity of background (including gender diversity) and experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest,
|
|
•
|
other factors that our committee may consider appropriate.
|
|
•
|
the highest personal and professional ethics and integrity;
|
|
•
|
proven achievement and competence in the nominee’s field and the ability to exercise sound business judgment;
|
|
•
|
skills that are complementary to those of the existing board;
|
|
•
|
the ability to assist and support management and make significant contributions to MaxLinear’s success; and
|
|
•
|
an understanding of the fiduciary responsibilities that are required of a member of the board and the commitment of time and energy necessary to diligently carry out those responsibilities.
|
|
|
Annualized Cash Fee(1)
|
||
|
Base Retainer
|
$
|
50,000
|
|
|
Lead Director
|
$
|
25,000
|
|
|
Audit Committee Chair(2)
|
$
|
20,000
|
|
|
Audit Committee Member
|
$
|
10,000
|
|
|
Compensation Committee Chair(2)
|
$
|
15,000
|
|
|
Compensation Committee Member
|
$
|
7,500
|
|
|
Nominating and Governance Committee Chair(2)
|
$
|
10,000
|
|
|
Nominating and Governance Committee Member
|
$
|
5,000
|
|
|
Strategy Development Committee Chair
|
$
|
10,000
|
|
|
Strategy Development Committee Member
|
$
|
5,000
|
|
|
(1)
|
All fees are payable on a quarterly basis.
|
|
(2)
|
Committee chairs receive both the fees applicable to such position and the fee applicable to committee membership.
|
|
Name
|
|
Fees Earned or Paid in Cash ($)
|
|
Stock Awards ($)(1)
|
|
Total ($)
|
|||
|
Daniel Artusi(2)
|
|
5,469
|
|
|
235,064
|
|
|
240,533
|
|
|
Carolyn Beaver(3)
|
|
5,000
|
|
|
233,254
|
|
|
238,254
|
|
|
Steven C. Craddock(4)(9)
|
|
77,500
|
|
|
165,000
|
|
|
242,500
|
|
|
Albert J. Moyer(5)(9)
|
|
85,000
|
|
|
165,000
|
|
|
250,000
|
|
|
Thomas E. Pardun(6)(9)
|
|
107,500
|
|
|
165,000
|
|
|
272,500
|
|
|
Donald E. Schrock(7)(9)
|
|
72,500
|
|
|
165,000
|
|
|
237,500
|
|
|
Theodore Tewksbury, Ph.D(8)(9)
|
|
74,583
|
|
|
165,000
|
|
|
239,583
|
|
|
(1)
|
Amounts shown do not reflect compensation actually received by the director. Instead, the amounts represent the aggregate grant-date fair value related to restricted stock awards, granted in the year indicated, pursuant to Accounting Standards Codification Topic 718. For a discussion of the valuation assumptions, see Note 9, Stock-Based Compensation and Employee Benefit Plans, to our consolidated financial statements included in our Annual Report on Form 10-K. The actual value that may be realized from an award is contingent upon the satisfaction of applicable conditions to vesting and the value of our common stock on the date the award is vested. Thus, there is no assurance that the value, if any, eventually realized will correspond to the amount shown. These shares vest, assuming continued service, on the earlier to occur of the next succeeding May 1 or the date immediately preceding the next annual meeting of stockholders.
|
|
(2)
|
Mr. Artusi joined our board of directors in November 2018. On
December 31, 2018
, 12,148 restricted stock units were outstanding.
|
|
(3)
|
Ms. Beaver joined our board of directors in December 2018. On
December 31, 2018
, 11,434 restricted stock units were outstanding.
|
|
(4)
|
Mr. Craddock will retire from the board of directors and is not standing for re-election at the annual meeting. On
December 31, 2018
, 19,103 restricted stock units were outstanding.
|
|
(5)
|
On
December 31, 2018
, 45,432 stock options and 19,103 restricted stock units were outstanding.
|
|
(6)
|
On
December 31, 2018
, 27,432 stock options and 19,103 restricted stock units were outstanding.
|
|
(7)
|
On
December 31, 2018
, 45,432 stock options and 19,103 restricted stock units were outstanding.
|
|
(8)
|
On
December 31, 2018
, 68,446 stock options and 19,103 restricted stock units were outstanding.
|
|
(9)
|
Amount includes restricted stock units for which settlement has been deferred.
|
|
•
|
to attract and retain talented and experienced executives;
|
|
•
|
to motivate and reward executives whose knowledge, skills and performance are critical to our success;
|
|
•
|
to ensure fairness among the executive management team by recognizing the contributions each executive makes to our success; and
|
|
•
|
to incentivize our executives to manage our business to meet our long-term objectives and the long-term objectives of our stockholders.
|
|
|
2018
|
|
2017
|
||||
|
Audit Fees(1)
|
$
|
1,148,132
|
|
|
$
|
1,828,848
|
|
|
Audit-Related Fees
|
—
|
|
|
—
|
|
||
|
Tax Fees
|
—
|
|
|
—
|
|
||
|
All Other Fees
|
—
|
|
|
—
|
|
||
|
Total
|
$
|
1,148,132
|
|
|
$
|
1,828,848
|
|
|
(1)
|
Audit fees for
2018
and
2017
consist of fees billed or to be billed by Grant Thornton LLP, including professional services rendered for quarterly, annual and other SEC filing activities, along with those audit services related to acquisitions and the implementation of new accounting standards. The decrease in fees from
2017
to
2018
primarily related to services related to our 2017 acquisitions, including Exar.
|
|
Name
|
|
Age
|
|
Position
|
|
Kishore Seendripu, Ph.D.
|
|
49
|
|
Chairman, President and Chief Executive Officer
|
|
Steven Litchfield
|
|
49
|
|
Chief Financial Officer and Chief Corporate Strategy Officer
|
|
Connie Kwong
|
|
40
|
|
Corporate Controller and Principal Accounting Officer
|
|
Michael J. LaChance
|
|
59
|
|
Vice President, Operations
|
|
Curtis Ling
|
|
53
|
|
Chief Technical Officer
|
|
James Lougheed
|
|
41
|
|
Vice President, Marketing, High Performance Analog
|
|
Madhukar Reddy, Ph.D.
|
|
49
|
|
Vice President, Central Engineering
|
|
William G. Torgerson
|
|
51
|
|
Vice President and General Manager, Broadband Group
|
|
Brendan Walsh
|
|
46
|
|
Vice President, Marketing Infrastructure
|
|
Michael Bollesen
|
|
51
|
|
Vice President, Sales
|
|
•
|
to attract and retain talented and experienced executives;
|
|
•
|
to motivate and reward executives whose knowledge, skills, and performance are critical to our success;
|
|
•
|
to ensure fairness among our executive management team by recognizing the contributions each executive makes to our success; and
|
|
•
|
to incentivize our executives to manage our business to meet our long-term objectives and the long-term objectives of our stockholders.
|
|
•
|
A portion of each executive’s 2019 restricted stock unit awards will be in the form of performance stock units that will only vest subject to satisfaction of financial performance milestones.
|
|
•
|
For our chief executive officer and chief financial officer, 2019 equity incentive grants will be weighted equally between performance stock units and time-based restricted stock units. For other executive officers, time-based restricted stock units will represent 75% of the executive’s total equity incentive award for 2019 with the balance consisting of performance stock units.
|
|
•
|
to oversee our overall compensation philosophy, compensation plans, and benefit programs and to make recommendations to our board of directors with respect to improvements or changes to such plans;
|
|
•
|
to review and approve all cash and equity compensation arrangements for our executive officers (including our chief executive officer); and
|
|
•
|
to oversee and administer our equity compensation plans.
|
|
•
|
Acacia Communications, Inc.
|
•
|
Inphi Corp.
|
•
|
Monolithic Power Systems, Inc.
|
|
•
|
Alpha & Omega Semiconductor, Inc.
|
•
|
Integrated Device Technology, Inc.
|
•
|
Power Integrations, Inc.
|
|
•
|
Ambarella, Inc.
|
•
|
IXYS Corporation
|
•
|
Quantenna Communications, Inc.
|
|
•
|
Cavium, Inc.
|
•
|
Knowles Corporation
|
•
|
Rambus Inc.
|
|
•
|
Cirrus Logic, Inc.
|
•
|
Lattice Semiconductor Corporation
|
•
|
Semtech Corporation
|
|
•
|
Cree, Inc.
|
•
|
MACOM Technology Solutions Holdings, Inc.
|
•
|
Silicon Laboratories, Inc.
|
|
•
|
Diodes Incorporated
|
•
|
Microsemi Corporation
|
|
|
|
•
|
base salary;
|
|
•
|
annual incentive compensation, which in recent years we have paid in the form of equity-based awards under our equity incentive plan;
|
|
•
|
equity-based incentives, principally in the form of time-based vesting of restricted stock units and, beginning in 2019, performance stock units;
|
|
•
|
benefits (on substantially similar terms as provided to our other employees); and
|
|
•
|
severance/termination protection, including in connection with certain change of control transactions, which were amended in December 2018 following consultation with Compensia concerning market practices and which are described in greater detail later in this section.
|
|
Executive Officer
|
|
Annual Base Salary(1)
|
||||||
|
|
2018
|
|
2019
|
|||||
|
Kishore Seendripu, Ph.D.
|
|
$
|
550,000
|
|
|
$
|
550,000
|
|
|
Steven Litchfield
|
|
$
|
360,000
|
|
|
$
|
360,000
|
|
|
Madhukar Reddy, Ph.D.
|
|
$
|
310,000
|
|
|
$
|
310,000
|
|
|
William G. Torgerson
|
|
$
|
300,000
|
|
|
$
|
300,000
|
|
|
Michael Bollesen
|
|
$
|
270,000
|
|
|
$
|
270,000
|
|
|
Adam C. Spice(2)
|
|
$
|
360,000
|
|
|
N/A
|
|
|
|
(1)
|
Reflects the highest annualized base salary established for the named executive officer during the year indicated.
|
|
(2)
|
Mr. Spice served as Vice President and Chief Financial Officer until May 2018.
|
|
Executive Officer
|
|
Total 2018 Bonus Targets
|
|
2018 Bonuses Paid
|
||||||||||
|
|
% Base Salary
|
|
Target ($)
|
|
Corporate Targets ($)
|
|
Individual Performance ($)
|
|
Total Bonus ($)
|
|||||
|
Kishore Seendripu, Ph.D.
|
|
110%
|
|
605,000
|
|
|
318,704
|
|
|
106,234
|
|
|
424,938
|
|
|
Steven Litchfield
|
|
70%
|
|
99,831
|
|
|
53,909
|
|
|
25,956
|
|
|
79,865
|
|
|
Madhukar Reddy, Ph.D.
|
|
60%
|
|
186,000
|
|
|
99,132
|
|
|
44,058
|
|
|
143,190
|
|
|
William G. Torgerson
|
|
60%
|
|
180,000
|
|
|
96,328
|
|
|
32,109
|
|
|
128,437
|
|
|
Michael Bollesen
|
|
60%
|
|
65,423
|
|
|
35,328
|
|
|
13,085
|
|
|
48,413
|
|
|
Adam C. Spice(1)
|
|
70%
|
|
252,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1)
|
Mr. Spice served as Vice President and Chief Financial Officer until May 2018.
|
|
Executive Officer
|
|
2019 Bonus Targets
|
|||
|
|
% Base Salary
|
|
Target ($)
|
||
|
Kishore Seendripu, Ph.D.
|
|
110%
|
|
605,000
|
|
|
Steven Litchfield
|
|
70%
|
|
252,000
|
|
|
Madhukar Reddy, Ph.D.
|
|
60%
|
|
186,000
|
|
|
William G. Torgerson
|
|
60%
|
|
180,000
|
|
|
Michael Bollesen
|
|
60%
|
|
162,000
|
|
|
Executive Officer
|
|
Shares Subject to Stock Options
|
|
Shares Subject to Restricted Stock Units
|
|
Total
|
|||
|
Kishore Seendripu, Ph.D.(1)
|
|
—
|
|
|
168,372
|
|
|
168,372
|
|
|
Steven Litchfield(2)(3)
|
|
306,000
|
|
|
52,000
|
|
|
358,000
|
|
|
Madhukar Reddy, Ph.D.(1)
|
|
—
|
|
|
48,491
|
|
|
48,491
|
|
|
William G. Torgerson(1)
|
|
—
|
|
|
43,103
|
|
|
43,103
|
|
|
Michael Bollesen(2)(4)
|
|
29,000
|
|
|
58,900
|
|
|
87,900
|
|
|
Adam C. Spice
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1)
|
Restricted stock units to vest quarterly over four (4) years with the first vesting event occurring on August 20, 2018 and the grants becoming fully vested on May 20, 2022, subject to the executive officer’s continuing to provide services to us on each applicable vesting date.
|
|
(2)
|
One-fourth (25%) of the restricted stock units will vest on August 20, 2019, and an additional one-sixteenth (1/16th) of the restricted stock units will vest on each successive November 20, February 20, May 20, and August 20 thereafter, such that the award will be fully vested on August 20, 2022, subject to the executive officer’s continuing to provide services to us on each applicable vesting date.
|
|
(4)
|
One-fourth (25%) of the stock options will vest and become exercisable on July 30, 2019, and an additional one-forty-eighth (1/48th) of the stock options will vest monthly, such that the award will be fully vested on July 30, 2022.
|
|
•
|
health, dental, and vision insurance;
|
|
•
|
life insurance;
|
|
•
|
employee stock purchase plan;
|
|
•
|
employee assistance plan;
|
|
•
|
medical and dependent care flexible spending account or health savings account;
|
|
•
|
short- and long-term disability, accidental death and dismemberment; and
|
|
•
|
a 401(k) plan.
|
|
•
|
a lump sum cash payment equal to twelve (12) months of the executive’s then-current base salary;
|
|
•
|
a lump sum cash payment equal to a pro-rated amount of his target annual bonus for the year of termination based on the number of days that occur between the start of the year and the date of termination;
|
|
•
|
reimbursement of premiums for continued health benefits under our health plans for up to twelve (12) months following the executive’s termination; provided that the executive constitutes a qualified beneficiary under applicable law and timely elects to continue coverage under applicable law;
|
|
•
|
any outstanding and unvested equity awards that would have vested within twelve (12) months following the date of termination solely based upon the executive’s continued service with the company would immediately vest at termination; and
|
|
•
|
extended exercisability of outstanding and vested stock options or stock appreciation rights until the twelve (12) month anniversary of the termination date; provided that in no event will the post-termination exercise period for any individual stock option extend beyond the original maximum term.
|
|
•
|
a lump sum cash payment equal to twenty-four (24) months of his base salary, determined at a rate equal to the greater of (A) his annual salary as in effect immediately prior to the change in control or (B) his then current base salary as of the date of such termination;
|
|
•
|
a lump sum cash payment equal to 200% of his target annual bonus for the year immediately preceding the year of the change in control, or if greater, the target bonus in effect immediately prior to the change in control;
|
|
•
|
reimbursement of premiums for continued health benefits under our health plans for up to twenty-four (24) months following the executive’s termination;
provided that
the executive constitutes a qualified beneficiary under applicable law and timely elects to continue coverage under applicable law;
|
|
•
|
immediate vesting of 100% of the then-unvested portion of any outstanding equity awards held by the executive; and
|
|
•
|
extended exercisability of outstanding and vested stock options or stock appreciation rights until the twenty-four (24) month anniversary of the termination date;
provided that
in no event will the post-termination exercise period for any individual stock option extend beyond the original maximum term.
|
|
•
|
a lump sum cash payment equal to six (6) months of the executive’s then-current base salary;
|
|
•
|
a lump sum cash payment equal to a pro-rated amount of his target annual bonus for the year of termination based on the number of days that occur between the start of the year and the date of termination;
|
|
•
|
reimbursement of premiums for continued health benefits under our health plans for up to six (6) months following the executive’s termination;
provided that
the executive constitutes a qualified beneficiary under applicable law and timely elects to continue coverage under applicable law;
|
|
•
|
any outstanding and unvested equity awards that would have vested within six (6) months following the date of termination solely based upon the executive’s continued service with the company would immediately vest at termination; and
|
|
•
|
extended exercisability of outstanding and vested stock options or stock appreciation rights until the six (6) month anniversary of the termination date; provided that in no event will the post-termination exercise period for any individual stock option extend beyond the original maximum term.
|
|
•
|
a lump sum cash payment equal to twelve (12) months of the executive’s base salary, determined at a rate equal to the greater of (A) his annual salary as in effect immediately prior to the change in control or (B) his then-current base salary as of the date of such termination;
|
|
•
|
a lump sum cash payment equal to 100% of his target annual bonus for the year immediately preceding the year of the change in control, or if greater, the target bonus in effect immediately prior to the change in control;
|
|
•
|
reimbursement of premiums for continued health benefits under our health plans for up to twelve (12) months following the executive’s termination;
provided that
the executive constitutes a qualified beneficiary under applicable law and timely elects to continue coverage under applicable law;
|
|
•
|
immediate vesting of one hundred percent (100%) of the then-unvested portion of any outstanding equity awards held by the executive; and
|
|
•
|
extended exercisability of outstanding and vested stock options or stock appreciation rights until the twelve (12) month anniversary of the termination date;
provided that
in no event would the post-termination exercise period for any individual stock option extend beyond the original term.
|
|
•
|
the median of the annual total compensation of all employees of our company (other than our CEO), was
$122,801
; and
|
|
•
|
the annual total compensation of our CEO, as reported in the Summary Compensation Table presented elsewhere in this proxy statement, was
$4,104,632
.
|
|
•
|
We selected
December 21, 2018
, as the date upon which we would identify the median employee.
|
|
•
|
As of
December 21, 2018
, our employee population consisted of approximately
738
individuals, including employees in the United States, Canada, China, France, Great Britain, Hong Kong, India, Ireland, Israel, Japan, Malaysia, Singapore, Spain, South Korea and Taiwan. Material changes in the assumptions used to identify the median employee include the addition of
166
employees of our G.hn and high-performance analog businesses as of
December 21, 2018
, who we acquired in transactions that closed in 2017. Such employees were previously excluded from the determination of our median employee.
|
|
•
|
To identify the “median employee” from our employee population, we used fiscal year
2018
payroll and stock-based compensation records (the “compensation measure”).
|
|
•
|
The compensation measure included base salary (including any paid overtime) and bonus payments.
|
|
•
|
We annualized the base salary of all permanent employees who did not work for us or our subsidiaries for the entire fiscal year.
|
|
•
|
Amounts paid in foreign currency were converted into United States dollars using average exchange rates in effect during fiscal year
2018
.
|
|
•
|
With respect to the annual total compensation of the “median employee,” we identified and calculated the elements of such employee’s compensation for fiscal year
2018
in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K, resulting in annual total compensation of
$122,801
.
|
|
•
|
With respect to the annual total compensation for the CEO, we used the amount reported in the “Total” column of our
2018
Summary Compensation Table.
|
|
Name and Principal Position
|
|
Year
|
|
Salary ($)
|
|
Stock Awards ($)(1)(2)
|
|
Option Awards ($)(3)
|
|
All Other Compensation ($)(4)
|
|
Total ($)
|
|||||
|
Kishore Seendripu, Ph.D.
|
|
2018
|
|
538,189
|
|
|
3,549,922
|
|
|
—
|
|
|
16,521
|
|
|
4,104,632
|
|
|
Chairman, President and Chief Executive
|
|
2017
|
|
492,299
|
|
|
2,802,171
|
|
|
—
|
|
|
13,511
|
|
|
3,307,981
|
|
|
Officer (Principal Executive Officer)
|
|
2016
|
|
464,747
|
|
|
2,854,213
|
|
|
—
|
|
|
14,985
|
|
|
3,333,945
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Steven Litchfield(5)
|
|
2018
|
|
142,806
|
|
|
969,585
|
|
|
2,491,054
|
|
|
9,851
|
|
|
3,613,296
|
|
|
Chief Financial Officer and Chief Corporate
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Strategy Officer (Principal Financial Officer)
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Madhukar Reddy, Ph.D.
|
|
2018
|
|
307,609
|
|
|
1,043,183
|
|
|
—
|
|
|
16,521
|
|
|
1,367,313
|
|
|
Vice President, Central Engineering
|
|
2017
|
|
293,858
|
|
|
1,090,012
|
|
|
—
|
|
|
13,495
|
|
|
1,397,365
|
|
|
|
|
2016
|
|
285,192
|
|
|
1,970,098
|
|
|
—
|
|
|
13,344
|
|
|
2,268,634
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
William G. Torgerson
|
|
2018
|
|
297,989
|
|
|
928,429
|
|
|
—
|
|
|
23,643
|
|
|
1,250,061
|
|
|
Vice President and General Manager,
|
|
2017
|
|
289,183
|
|
|
1,168,810
|
|
|
—
|
|
|
16,588
|
|
|
1,474,581
|
|
|
Broadband Group
|
|
2016
|
|
284,962
|
|
|
1,850,515
|
|
|
—
|
|
|
14,941
|
|
|
2,150,418
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Michael Bollesen(6)
|
|
2018
|
|
109,795
|
|
|
1,102,723
|
|
|
236,080
|
|
|
6,867
|
|
|
1,455,465
|
|
|
Vice President, Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Adam C. Spice(7)
|
|
2018
|
|
151,904
|
|
|
—
|
|
|
—
|
|
|
6,877
|
|
|
158,781
|
|
|
Former Vice President and Chief Financial
|
|
2017
|
|
338,901
|
|
|
1,500,402
|
|
|
—
|
|
|
13,511
|
|
|
1,852,814
|
|
|
Officer (Former Principal Financial Officer)
|
|
2016
|
|
330,196
|
|
|
2,432,077
|
|
|
—
|
|
|
13,371
|
|
|
2,775,644
|
|
|
(1)
|
Includes for 2018 the issuance of shares of our common stock for the 2018 corporate performance period under our executive incentive bonus plan. Awards were valued in accordance with Accounting Standards Codification Topic 718, or ASC 718. Individual awards for executive performance during 2018 were made on February 22, 2019 for the following amounts: Dr. Seendripu, $424,938; Mr. Litchfield, $79,865; Dr. Reddy, $143,190; Mr. Torgerson, $128,437; and Mr. Bollesen, $48,413. Includes for 2017 the issuance of shares of our common stock for the 2017 corporate performance period under our executive incentive bonus plan and additional bonus awards for 2017 to certain executives granted by the compensation committee. Awards were valued in accordance with Accounting Standards Codification Topic 718, or ASC 718. Individual awards for executive performance during 2017 were made on February 23, 2018 for the following amounts: Dr. Seendripu, $302,195; Dr. Reddy, $90,031; Mr. Torgerson, $118,810; and Mr. Spice, $150,406. Additional bonus awards for 2017 were made on February 28, 2018 for the following amounts: Dr. Reddy, $200,000; Mr. Torgerson, $350,000; and Mr. Spice, $350,000. Includes for 2016 the issuance of shares of our common stock for the 2016 corporate performance period under our executive incentive bonus plan. Individual awards for executive performance during the first half of the 2016 year were valued in accordance with ASC 718 and were made on August 12, 2016 for the following amounts: Dr. Seendripu, $311,599; Dr. Reddy, $95,036; Mr. Torgerson, $113,006; and Mr. Spice, $144,089. Individual awards for executive performance during the second half of the 2016 year were made on February 17, 2017 for the following amounts: Dr. Seendripu, $242,614; Dr. Reddy, $75,062; Mr. Torgerson $87,509; and Mr. Spice, $112,988.
|
|
(2)
|
Includes for 2018 grants of restricted stock units (RSUs) in the following amounts: Dr. Seendripu, $3,124,984; Mr. Litchfield, $889,720; Dr. Reddy, $899,993; Mr. Torgerson, $799,992; and Mr. Bollesen, $1,054,310. Includes for 2017 grants of RSUs in the following amounts: Dr. Seendripu, $2,499,976; Dr. Reddy, $799,981; Mr. Torgerson, $700,000; and Mr. Spice, $999,996. Includes for 2016 grants of RSUs in the following amounts: Dr. Seendripu, $2,300,000; Dr. Reddy, $1,800,000; Mr. Torgerson, $1,650,000 and Mr. Spice, $2,175,000. The dollar value of the RSUs shown represents the aggregate grant date fair value computed pursuant to ASC 718 and attributable to RSU awards granted to these individuals
|
|
(4)
|
Represents employer funded amounts for group term life insurance, disability insurance, and medical, dental and vision insurance premiums.
|
|
(5)
|
Mr. Litchfield joined MaxLinear on July 1, 2018, and his compensation included in the table above is from his start date.
|
|
Name
|
|
Grant Date
|
|
Estimated Future Payments Under Equity Incentive Plan Awards(1)
|
|
All Other Stock Awards: Number of Shares of Stock or Units (#)
|
|
All Other Option Awards: Number of Securities Underlying Options (#)
|
|
Exercise or Base Price of Option Awards ($/Sh)
|
|
Grant Date Fair Value of Stock and Option Awards ($)(4)
|
|||||||||||
|
|
Threshold ($)
|
|
Target ($)
|
|
Maximum ($)
|
|
|||||||||||||||||
|
Kishore Seendripu, Ph.D.
|
|
2/22/2019
|
|
—
|
|
|
605,000
|
|
|
907,500
|
|
|
17,983(1)
|
|
|
—
|
|
|
—
|
|
|
424,938(1)
|
|
|
|
|
5/24/2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
168,372(2)
|
|
|
—
|
|
|
—
|
|
|
3,124,984(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Steven Litchfield
|
|
2/22/2019
|
|
—
|
|
|
99,831
|
|
|
149,747
|
|
|
3,379(1)
|
|
|
—
|
|
|
—
|
|
|
79,865(1)
|
|
|
|
|
8/10/2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
306,000(3)
|
|
|
18.40
|
|
|
2,491,054(3)
|
|
|
|
|
7/18/2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
52,000(2)
|
|
|
—
|
|
|
—
|
|
|
889,720(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Madhukar Reddy, Ph.D.
|
|
2/22/2019
|
|
—
|
|
|
186,000
|
|
|
279,000
|
|
|
6,059(1)
|
|
|
—
|
|
|
—
|
|
|
143,190(1)
|
|
|
|
|
5/24/2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
48,491(2)
|
|
|
—
|
|
|
—
|
|
|
899,993(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
William G. Torgerson
|
|
2/22/2019
|
|
—
|
|
|
180,000
|
|
|
270,000
|
|
|
5,435(1)
|
|
|
—
|
|
|
—
|
|
|
128,437(1)
|
|
|
|
|
5/24/2018
|
|
—
|
|
|
|
|
|
|
43,103(2)
|
|
|
—
|
|
|
—
|
|
|
799,992(2)
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Michael Bollesen
|
|
2/22/2019
|
|
—
|
|
|
65,423
|
|
|
98,135
|
|
|
2,048(1)
|
|
|
—
|
|
|
—
|
|
|
48,413(1)
|
|
|
|
|
8/10/2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
29,000(3)
|
|
|
18.40
|
|
|
236,080(3)
|
|
|
|
|
8/07/2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
58,900(2)
|
|
|
—
|
|
|
—
|
|
|
1,054,310(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Adam C. Spice
|
|
—
|
|
—
|
|
|
252,000
|
|
|
378,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1)
|
Awards for the 2018 corporate performance period under our executive incentive bonus plan were settled in shares of our common stock in February 2019. A complete description of the terms of our executive incentive bonus plan is set forth above under the caption “Annual Incentive Program for 2018 Corporate Performance Period.” The grant date fair value calculated under ASC 718 for awards under our executive incentive bonus plan are included in the “Stock Awards Column” of the Summary Compensation Table and in the final column of this table. The number of shares subject to the awards is calculated on the grant date based on the closing sales price of our common stock on that date. The grant dates are the effective dates that the Board approved the bonus award amounts.
|
|
(2)
|
These stock awards represent restricted stock units issued under our 2010 Equity Incentive Plan, as amended. Each restricted stock unit entitles the executive to receive one (1) share of our common stock at the time of vesting without the payment of an exercise price or other consideration. The shares granted on May 24, 2018 subject to restricted stock units vest quarterly over four (4) years. The shares granted on July 18, 2018 for Mr. Litchfield and on August 7, 2018 for Mr. Bollesen subject to restricted stock units vest as follows: one-fourth (25%) of the restricted stock units will vest on August 20, 2019, and an additional one-sixteenth (1/16th) of the restricted stock units will vest on each successive November 20, February 20, May 20, and August 20 thereafter, such that the award will be fully vested on August 20, 2022. Unvested restricted stock units are subject to acceleration of vesting in certain situations such as in connection with a change of control.
|
|
(4)
|
The shares of common stock underlying restricted stock unit awards and stock options were valued as of their respective grant dates in accordance with ASC 718. Our assumptions with respect to the calculation of stock-based compensation expense are set forth in Note 9, Stock-Based Compensation and Employee Benefit Plans, to our consolidated financial statements included in our Annual Report on Form 10-K.
|
|
Name
|
|
Option Awards
|
|
Option Expiration Date
|
|
Stock Awards
|
||||||||||||
|
|
Number of Securities Underlying Unexercised Options Exercisable (#)
|
|
Number of Securities Underlying Unexercised Options Unexercisable (#)
|
|
Option Exercise Price ($)
|
|
|
Number of Shares or Units of Stock That Have Not Vested (#)
|
|
Market Value of Restricted Stock Units That Have Not Vested ($)
|
||||||||
|
Kishore Seendripu, Ph.D.
|
|
86,110(1)
|
|
|
—
|
|
|
4.69
|
|
|
7/28/2019
|
|
|
|
|
|
||
|
|
|
226,039(1)
|
|
|
—
|
|
|
8.19
|
|
|
10/27/2019
|
|
|
|
|
|
||
|
|
|
200,000(1)
|
|
|
—
|
|
|
4.81
|
|
|
5/10/2019
|
|
|
|
|
|
||
|
|
|
186,440(1)
|
|
|
—
|
|
|
6.93
|
|
|
5/14/2020
|
|
|
|
|
|
||
|
|
|
105,437(1)
|
|
|
—
|
|
|
9.23
|
|
|
6/2/2021
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
16,875(2)
|
|
|
297,000(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
41,758(4)
|
|
|
734,941(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
52,590(5)
|
|
|
925,584(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
147,326(6)
|
|
|
2,592,938(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Steven Litchfield
|
|
—
|
|
|
306,000(9)
|
|
|
18.40
|
|
|
8/10/2025
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
52,000(7)
|
|
|
915,200(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Madhukar Reddy, Ph.D.
|
|
80,000(1)
|
|
|
|
|
4.81
|
|
|
5/10/2019
|
|
|
|
|
|
|||
|
|
|
50,000(1)
|
|
|
|
|
5.64
|
|
|
8/9/2019
|
|
|
|
|
|
|||
|
|
|
59,986(1)
|
|
|
|
|
6.93
|
|
|
5/14/2020
|
|
|
|
|
|
|||
|
|
|
33,402(1)
|
|
|
|
|
9.23
|
|
|
6/2/2021
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
7,125(2)
|
|
|
125,400(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
12,709(4)
|
|
|
223,678(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
36,823(8)
|
|
|
648,085(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
16,828(5)
|
|
|
296,173(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
42,430(6)
|
|
|
746,768(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
William G. Torgerson
|
|
25,051(1)
|
|
|
—
|
|
|
9.23
|
|
|
6/2/2021
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
5,500(2)
|
|
|
96,800(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
11,801(4)
|
|
|
207,698(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
33,476(8)
|
|
|
589,178(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
14,725(5)
|
|
|
259,160(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
37,716(6)
|
|
|
663,802(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Michael Bollesen
|
|
—
|
|
|
29,000(10)
|
|
|
18.40
|
|
|
8/10/2025
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
58,900(7)
|
|
|
1,036,640(3)
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Adam C. Spice
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1)
|
This stock option has fully vested.
|
|
(2)
|
Subject to the award recipient continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one-sixteenth(1/16th) of the restricted stock units subject to the award will vest on August 20, 2015, and one-sixteenth (1/16th) of the restricted stock units will vest on each successive November 20, February 20, May 20, and August 20 thereafter, such that the award will be fully vested on May 20, 2019.
|
|
(3)
|
Based on the closing price of $17.60 of MaxLinear’s common stock on December 31, 2018.
|
|
(4)
|
Subject to the award recipient continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one sixteenth (1/16th) of the restricted stock units will vest on February 20, 2016, and one sixteenth (1/16th) of the restricted stock units will vest on each successive May 20, August 20, November 20, and February 20 thereafter, such that the award will be fully vested on November 20, 2019.
|
|
(5)
|
Subject to the award recipient continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one sixteenth (1/16th) of the RSUs will vest on May 20, 2017, and one sixteenth (1/16th) of the restricted stock units will vest on each successive August 20, November 20, February 20, and May 20 thereafter, such that the award will be fully vested on February 20, 2021.
|
|
(6)
|
Subject to the award recipient continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one sixteenth (1/16th) of the restricted stock units will vest on August 20, 2018, and one sixteenth (1/16th) of the restricted stock units will vest on each successive November 20, February 20, May 20, and August 20, thereafter, such that the award will be fully vested on May 20, 2022.
|
|
(7)
|
Subject to the award recipient continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one-fourth (25%) of the restricted stock units will vest on August 20, 2019, and an additional one-sixteenth (1/16th) of the restricted stock units will vest on each successive November 20, February 20, May 20, and August 20 thereafter, such that the award will be fully vested on August 20, 2022.
|
|
(8)
|
Subject to the award recipient continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, ten percent (10%) of the restricted stock units will vest on August 20, 2017; twenty percent (20%) of the restricted stock units will vest on August 20, 2018; thirty percent (30%) of the restricted stock units will vest on August 20, 2019; and forty percent (40%) of the restricted stock units will vest on August 20, 2020.
|
|
(9)
|
Subject to the optionee continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one-fourth (25%) of the options will vest and become exercisable on July 2, 2019, and an additional one-forty-eighth (1/48th) of the shares subject to the options will vest monthly, such that the award will be fully vested on July 2, 2022.
|
|
(10)
|
Subject to the optionee continuing to be a service provider (as defined in the 2010 Equity Incentive Plan) through each applicable vesting date, one-fourth (25%) of the options will vest and become exercisable on July 30, 2019, and an additional one-forty-eighth (1/48th) of the shares subject to the options will vest monthly, such that the award will be fully vested on July 30, 2022.
|
|
|
|
Number of Shares Acquired on Exercise (#)
|
|
Value Realized on Exercise ($)(1)
|
||
|
Kishore Seendripu, Ph.D.
|
|
60,000
|
|
|
792,600
|
|
|
Steven Litchfield
|
|
—
|
|
|
—
|
|
|
Madhukar Reddy, Ph.D.
|
|
—
|
|
|
—
|
|
|
William G. Torgerson
|
|
—
|
|
|
—
|
|
|
Michael Bollesen
|
|
—
|
|
|
—
|
|
|
Adam C. Spice
|
|
239,864
|
|
|
2,697,778
|
|
|
(1)
|
Represents the difference between the closing price of a share of our common stock on the date of exercise less the strike price of the stock option, multiplied by the number of shares underlying the option exercised.
|
|
|
|
Number of Shares Acquired on Vesting (#)
|
|
Value Realized on Vesting ($)(1)(2)
|
||
|
Kishore Seendripu, Ph.D.
|
|
122,956
|
|
|
2,524,445
|
|
|
Steven Litchfield
|
|
—
|
|
|
—
|
|
|
Madhukar Reddy, Ph.D.
|
|
61,142
|
|
|
1,245,407
|
|
|
William G. Torgerson
|
|
62,036
|
|
|
1,286,568
|
|
|
Michael Bollesen
|
|
—
|
|
|
—
|
|
|
Adam C. Spice
|
|
47,435
|
|
|
1,050,230
|
|
|
(1)
|
Represents the closing price of a share of our common stock on the date of vesting multiplied by the number of shares that have vested.
|
|
(2)
|
Value realized on vesting attributable to certain vested restricted stock units for certain named executive officers is deferred pending settlement of the vested restricted stock units. Settlement of the restricted stock units is deferred as described in “
Executive Compensation - Non-Qualified Deferred Compensation
.” Amounts deferred for each of the named executive officers is as follows: Dr. Seendripu, $392,508; Mr. Litchfield, none; Dr. Reddy, $113,038; Mr. Torgerson, $100,467; Mr. Bollesen, none; and Mr. Spice, none.
|
|
Name
|
|
Registrant Contributions in Last FY ($)(1)
|
|
Aggregate Earnings (Loss) in Last FY ($)(2)
|
|
Aggregate Balance at Last FYE ($)(3)
|
|||
|
Kishore Seendripu, Ph.D.
|
|
392,508
|
|
|
(22,098
|
)
|
|
370,410
|
|
|
Steven Litchfield
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Madhukar Reddy, Ph.D.
|
|
113,038
|
|
|
(6,364
|
)
|
|
106,674
|
|
|
William Torgerson
|
|
100,467
|
|
|
(5,656
|
)
|
|
94,811
|
|
|
Michael Bollesen
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Adam Spice
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1)
|
Represents the value, as of the applicable vesting date in
2018
, of the restricted stock units that vested and were earned and deferred by the officers in
2018
. Such awards are included as
2018
compensation in the
2018
Summary Compensation Table under the Stock Awards column. The value of each vested deferred restricted stock unit is based on the closing price of the Company’s common stock on the applicable vesting date.
|
|
(2)
|
Represents the net decrease in value of the shares underlying vested deferred settlement restricted stock units from the vesting date to
December 31, 2018
for each officer.
|
|
(3)
|
Represents the aggregate value of the vested deferred restricted stock units held by each officer as of
December 31, 2018
. The value of each vested deferred restricted stock unit is based on the closing price of the Company’s common stock on
December 31, 2018
.
|
|
Name
|
|
Terminated Without Cause or Terminated for Good Reason in Connection with a Change of Control(1)
|
||||||||||
|
|
Severance Payments Attributable to Salary ($)(2)
|
|
Severance Payments Attributable to Bonus ($)(3)
|
|
Acceleration of Equity Vesting ($)(4)
|
|
Health Care Benefits ($)(5)
|
|||||
|
Kishore Seendripu, Ph.D.
|
|
1,100,000
|
|
|
1,210,000
|
|
|
4,550,462
|
|
|
32,376
|
|
|
Steven Litchfield
|
|
720,000
|
|
|
504,000
|
|
|
915,200
|
|
|
46,905
|
|
|
Madhukar Reddy, Ph.D.
|
|
310,000
|
|
|
186,000
|
|
|
2,040,104
|
|
|
16,188
|
|
|
William G. Torgerson
|
|
300,000
|
|
|
180,000
|
|
|
1,816,637
|
|
|
23,453
|
|
|
Michael Bollesen
|
|
270,000
|
|
|
162,000
|
|
|
1,036,640
|
|
|
16,188
|
|
|
Adam C. Spice
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Name
|
|
Terminated Without Cause or Terminated for Good Reason NOT in Connection with a Change of Control(1)
|
||||||||||
|
|
Severance Payments Attributable to Salary ($)(2)
|
|
Severance Payments Attributable to Bonus ($)(3)
|
|
Acceleration of Equity Vesting ($)(4)
|
|
Health Care Benefits ($)(5)
|
|||||
|
Kishore Seendripu, Ph.D.
|
|
550,000
|
|
|
605,000
|
|
|
2,184,142
|
|
|
16,188
|
|
|
Steven Litchfield
|
|
360,000
|
|
|
252,000
|
|
|
286,000
|
|
|
23,453
|
|
|
Madhukar Reddy, Ph.D.
|
|
155,000
|
|
|
186,000
|
|
|
409,710
|
|
|
8,094
|
|
|
William G. Torgerson
|
|
150,000
|
|
|
180,000
|
|
|
353,074
|
|
|
11,726
|
|
|
Michael Bollesen
|
|
135,000
|
|
|
162,000
|
|
|
—
|
|
|
8,094
|
|
|
Adam C. Spice
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1)
|
A termination is considered to be “in connection with a change of control” if employment with us is either (i) terminated by us or our successor without cause or (ii) terminated by the executive for good reason, and in either event, during the period beginning three (3) months prior to and ending twenty four (24) months following a change of control.
|
|
(2)
|
The amounts shown in this column are based on such named executive officer’s base salary as of December 31, 2018.
|
|
(3)
|
The amounts shown in this column for the named executive officers represent an amount up to 100% to 200% of the executive’s target annual bonus for 2018.
|
|
(4)
|
The amounts shown in this column are equal to the spread value between (i) 100% of the unvested portion of all outstanding equity awards held by the named executive officer on December 31, 2018 and (ii) the difference between the closing market price on
December 31, 2018
of $17.60 per share and the exercise price, if any.
|
|
Plan category
|
|
(a)
Number of securities to be issued upon exercise of outstanding options, warrants and rights
|
|
(b)
Weighted- average exercise price of outstanding options, warrants, and rights
|
|
(c)
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
|
|||
|
Equity compensation plans approved by security holders(1)(2)(3)(4)
|
|
5,363,504(5)
|
|
|
$8.67(6)
|
|
|
10,157,798
|
|
|
Equity compensation plans not approved by security holders
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Total
|
|
5,363,504(5)
|
|
|
$8.67(6)
|
|
|
10,157,798
|
|
|
(1)
|
Consists of 2004 Stock Plan, 2010 Equity Incentive Plan, and the 2010 Employee Stock Purchase Plan.
|
|
(2)
|
Our 2010 Equity Incentive Plan provides for annual increases in the number of shares available for issuance thereunder on the first day of each fiscal year, equal to the least of (A) 2,583,311 shares of our common stock, (B) four percent (4%) of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year, or (C) such lesser amount as our board of directors or a designated committee acting as plan administrator may determine. Our 2010 Employee Stock Purchase Plan provides for annual increases in the number of shares available for issuance thereunder on the first day of each fiscal year, equal to the least of (A) 968,741 shares of our common stock, (B) one and a quarter
|
|
(3)
|
This table does not include securities to be issued under outstanding options, warrants or rights assumed by us in connection with our acquisition of Entropic, which consists of options or rights to acquire 124,701 shares of our common stock with a per share weighted-average exercise price of $16.43 under the terms of the Entropic Communications, Inc. 2007 Equity Incentive Plan, and Entropic Communications, Inc. 2007 Non-Employee Directors’ Stock Option Plan.
|
|
(4)
|
This table does not include securities to be issued under outstanding options, warrants or rights assumed by us in connection with our acquisition of Exar, which consists of options or rights to acquire 433,875 shares of our common stock with a per share weighted-average exercise price of $16.28 under the terms of the Exar Corporation 2006 Equity Incentive Plan, Sipex Corporation 2006 Equity Incentive Plan and Exar Corporation 2014 Equity Incentive Plan.
|
|
(5)
|
Includes 3,263,379 shares of our common stock subject to restricted stock units that entitle each holder to one (1) share of common stock for each such unit that vests over the holder’s period of continued service.
|
|
(6)
|
Calculated without taking into account the 3,263,379 shares of common stock subject to outstanding restricted stock units that become issuable as those units vest, without any cash consideration or other payment required for such shares.
|
|
•
|
Each person whom we know beneficially owns more than five percent of our common stock;
|
|
•
|
Each of our directors and named executive officers; and
|
|
•
|
All of our directors and current executive officers as a group.
|
|
Name and Address of Beneficial Owner
|
|
Shares Beneficially Owned
|
|||
|
|
Common Stock
|
||||
|
|
Shares
|
|
Percentage (%)
|
||
|
Executive Officers and Directors:
|
|
|
|
|
|
|
Kishore Seendripu, Ph.D(1)
|
|
4,675,993
|
|
|
6.57
|
|
Steven Litchfield(2)
|
|
2,008
|
|
|
*
|
|
Madhukar Reddy, Ph.D(3)
|
|
452,046
|
|
|
*
|
|
William G. Torgerson(4)
|
|
141,742
|
|
|
*
|
|
Michael Bollesen(5)
|
|
1,211
|
|
|
*
|
|
Adam C. Spice(6)
|
|
431,790
|
|
|
*
|
|
Daniel Artusi(7)
|
|
3,621
|
|
|
*
|
|
Carolyn Beaver(8)
|
|
3,346
|
|
|
*
|
|
Steven C. Craddock(9)
|
|
53,752
|
|
|
*
|
|
Albert J. Moyer(10)
|
|
65,565
|
|
|
*
|
|
Thomas E. Pardun(11)
|
|
77,109
|
|
|
*
|
|
Donald E. Schrock(12)
|
|
52,560
|
|
|
*
|
|
Theodore Tewksbury, Ph.D(13)
|
|
98,900
|
|
|
*
|
|
All directors and executive officers as a group (17 people)(14)
|
|
7,148,676
|
|
|
9.97
|
|
5% Stockholders:
|
|
|
|
|
|
|
BlackRock, Inc(15)
|
|
9,082,476
|
|
|
12.88
|
|
The Vanguard Group(16)
|
|
6,486,865
|
|
|
9.20
|
|
PRIMECAP Management Company(17)
|
|
4,820,444
|
|
|
6.83
|
|
Macquarie Group Ltd(18)
|
|
4,816,410
|
|
|
6.83
|
|
AllianceBernstein L.P.(19)
|
|
3,590,251
|
|
|
5.09
|
|
(*)
|
Represents beneficial ownership of less than 1%.
|
|
(1)
|
Common stock includes: (a) 604,026 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; (b) 242,826 shares of common stock; and (c) 24,720 restricted stock units that are scheduled to vest within sixty days of
March 25, 2019
, each held by Dr. Seendripu. Additional shares of common stock include: (a) 18,920 shares held of record by the Seendripu Relatives Trust (“Relatives Trust”); and (b) 3,785,501 shares held of record by the Seendripu Family Trust (“Family Trust”). Kishore V. Seendripu, a member of our board of directors and Named Executive Officer, is a trustee of the Relatives Trust and the Family Trust. Rekha Seendripu, Kishore V. Seendripu’s spouse, is a trustee of the Family Trust.
|
|
(2)
|
Consists of 2,008 shares of common stock held by Mr. Litchfield.
|
|
(3)
|
Common stock includes: (a) 143,388 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; (b) 300,049 shares of common stock; and (c) 8,609 restricted stock units that are scheduled to vest within sixty days of
March 25, 2019
, held by Dr. Reddy.
|
|
(4)
|
Common stock includes: (a) 25,051 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; (b) 109,355 shares of common stock; and (c) 7,336 restricted stock units that are scheduled to vest within sixty days of
March 25, 2019
, held by Mr. Torgerson.
|
|
(5)
|
Consists of 1,211 shares of common stock held by Mr. Bollesen.
|
|
(6)
|
Consists of 431,790 shares of common stock held by Mr. Spice.
|
|
(7)
|
Consists of 3,621 shares of common stock held by Mr. Artusi.
|
|
(8)
|
Consists of 3,346 shares of common stock held by Ms. Beaver.
|
|
(9)
|
Consists of 53,752 shares of common stock held by Mr. Craddock.
|
|
(10)
|
Common stock includes: (a) 10,857 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; and (b) 54,708 shares of common stock held by Mr. Moyer.
|
|
(11)
|
Common stock includes: (a) 10,857 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; and (b) 66,252 shares of common stock held by Mr. Pardun.
|
|
(12)
|
Common stock includes: (a) 10,857 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; and (b) 41,703 shares of common stock held by Mr. Schrock.
|
|
(13)
|
Common stock includes: (a) 68,446 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; and (b) 30,454 shares of common stock held by Dr. Tewksbury.
|
|
(14)
|
Common stock includes: (a) 1,104,218 shares of common stock subject to options exercisable within 60 days of
March 25, 2019
; (b) 5,969,974 shares of common stock; and (c) 74,484 restricted stock units that are scheduled to vest within sixty days of
March 25, 2019
, held of record by the current directors and executive officers.
|
|
(15)
|
Based solely on the most recently available Schedule 13G/A filed by BlackRock, Inc. with the SEC on January 31, 2019. BlackRock Inc. reported sole voting power over 8,938,845 shares and sole dispositive power over 9,082,476 shares. BlackRock, Inc. is a parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). The address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.
|
|
(17)
|
Based solely on the most recently available Schedule 13G/A filed by PRIMECAP Management Company with the SEC on February 8, 2019. PRIMECAP Management Company reported sole voting power over 3,929,922 shares and sole dispositive power over 4,820,444 shares. PRIMECAP Management Company is an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). The address of PRIMECAP Management Company is 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105.
|
|
(18)
|
Based solely on the most recently available Schedule 13G/A jointly filed by Macquarie Group Limited, Macquarie Bank Limited, Macquire Investment Management Holdings, Inc and Macquarie Investment Management Business Trust (together, “Macquarie”) with the SEC on February 14, 2019. Macquarie Investment Management Holdings Inc and Macquarie Investment Management Business Trust each reported sole voting power over 4,801,045 shares and sole dispositive power over 4,801,045 shares. Macquarie is an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E) and a parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). The address of Macquarie Group Limited and Macquarie Bank Limited is 50 Martin Place Sydney, New South Wales, Australia and the address of Macquarie Investment Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103.
|
|
(19)
|
Based solely on the most recently available Schedule 13G filed by AllianceBernstein L.P. with the SEC on February 13, 2019. AllianceBernstein L.P. reported sole voting power over 2,939,787 shares, sole dispositive power over 3,587,251 shares and shared dispositive power over 3,000 shares. AllianceBernstein L.P. is an investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). The address of AllianceBernstein L.P. is 1345 Avenue of the Americas, New York NY 10105.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|